Author: Belyaeva Tamara A. Nicol Clare Cesur Özlem Travé Gilles Blair George Eric Stonehouse Nicola J.
Publisher: MDPI
E-ISSN: 2072-6694|6|3|1553-1569
ISSN: 2072-6694
Source: Cancers, Vol.6, Iss.3, 2014-07, pp. : 1553-1569
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Human papillomavirus 16 (HPV16) is a high-risk DNA tumour virus which is the primary causative agent of cervical cancer. Cell transformation arises from deregulated expression of the E6 and E7 oncogenes. E6 has been shown to bind a number of cellular proteins, including p53 and proteins containing a PDZ domain. This study reports the first RNA aptamers to E6. These have been employed as molecular tools to further investigate E6-p53 and E6-PDZ interactions. This study is focussed on two aptamers (termed F2 and F4) which induced apoptosis in cells derived from an HPV16-transformed cervical carcinoma. The molecules were able to inhibit the interaction between E6 and PDZ1 from Magi1, with F2 being the most effective inhibitor. Neither of the aptamers inhibited E6-p53 interaction or p53 degradation. This study shows the specificity of this approach and highlights the potential benefits of the E6 aptamers as potential therapeutic or diagnostic agents in the future.
Related content
By Jimenez Jimenez Ana Maria Ruttkay-Nedecky Branislav Dostalova Simona Krejcova Ludmila Michalek Petr Richtera Lukas Adam Vojtech
International Journal of Molecular Sciences, Vol. 17, Iss. 5, 2016-05 ,pp. :
By Ding Chaofeng Cheng Shaobing Yang Zhe Lv Zhen Xiao Heng Du Chengli Peng Chuanhui Xie Haiyang Zhou Lin Wu Jian Zheng Shusen
International Journal of Molecular Sciences, Vol. 15, Iss. 3, 2014-03 ,pp. :
Functional Roles of E6 and E7 Oncoproteins in HPV-Induced Malignancies at Diverse Anatomical Sites
Cancers, Vol. 8, Iss. 10, 2016-10 ,pp. :
By Manfredi Francesco di Bonito Paola Ridolfi Barbara Anticoli Simona Arenaccio Claudia Chiozzini Chiara Baz Morelli Adriana Federico Maurizio
Vaccines, Vol. 4, Iss. 4, 2016-11 ,pp. :